Soo-Yong Tan

Dr. Soo-Yong Tan

Pathology, National University of Singapore, Singapore, Central Singapore, Singapore
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2014 in Blood
Verified
Journal Article
Open access
PDF file
JIJaveed Iqbal
Javeed Iqbal
GWGeorge Wright
George Wright
CWChao Wang
Chao Wang
ARAndreas Rosenwald
Andreas Rosenwald
RGRandy D. Gascoyne
Randy D. Gascoyne
LSLouis M. Staudt
Louis M. Staudt
Key Points: Diagnostic signatures for PTCL subtypes and 2 novel subgroups with distinct oncogenic pathway and prognostic importance in PTCL-NOS were identified. Demonstrated that ALK(–) ALCL is a distinct molecular entity and the tumor microenvironment has prognostic significance in AITL patients.

11 May 2015 in Nature
Verified
Journal Article
Closed access
CKCheryl M. Koh
Cheryl M. Koh
MBMarco Bezzi
Marco Bezzi
DLDiana H. P. Low
Diana H. P. Low
WAWei Xia Ang
Wei Xia Ang
STShun Xie Teo
Shun Xie Teo
EGErnesto Guccione
Ernesto Guccione

1 July 2012 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
GKGhee Chong Koo
Ghee Chong Koo
STSoo-Yong Tan
Soo-Yong Tan
TTTiffany Tang
Tiffany Tang
SPSong Ling Poon
Song Ling Poon
GAGeorge E. Allen
George E. Allen
SLSoon Thye Lim
Soon Thye Lim
The molecular pathogenesis of natural killer/T-cell lymphoma (NKTCL) is not well understood. We conducted whole-exome sequencing and identified Janus kinase 3 (JAK3) somatic–activating mutations (A572V and A573V) in 2 of 4 patients with NKTCLs. Further validation of the prevalence of JAK3 mutations was determined by Sanger sequencing and high-resolution melt (HRM) analysis in an additional 61 cases. In total, 23 of 65 (35.4%) cases harbored JAK3 mutations. Functional characterization of the JAK3 mutations support its involvement in cytokine-independent JAK/STAT constitutive activation leading to increased cell growth. Moreover, treatment of both JAK3-mutant and wild-type NKTCL cell lines with a novel pan-JAK inhibitor, CP-690550, resulted in dose-dependent reduction of phosphorylated STAT5, reduced cell viability, and increased apoptosis. Hence, targeting the deregulated JAK/STAT pathway could be a promising therapy for patients with NKTCLs. Significance: Gene mutations causing NKTCL have not been fully identified. Through exome sequencing, we identified activating mutations of JAK3 that may play a significant role in the pathogenesis of NKTCLs. Our findings have important implications for the management of patients with NKTCLs. Cancer Discov; 2(7); 591–7. ©2012 AACR. This article is highlighted in the In This Issue feature, p. 569.

1 May 2018 in The Lancet
Verified
Journal Article
Closed access
SSShahin Sayed
Shahin Sayed
WCWilliam Cherniak
William Cherniak
MLMark Lawler
Mark Lawler
STSoo-Yong Tan
Soo-Yong Tan
WSWafaa El Sadr
Wafaa El Sadr
KFKenneth A Fleming
Kenneth A Fleming

1 May 2003 in Oncogene
Verified
Journal Article
Closed access
Caroline LeeCaroline Lee
Caroline Lee
JRJianwei Ren
Jianwei Ren
ICIan Sy Cheong
Ian Sy Cheong
KBKenneth Ban
Kenneth Ban
LOLondon Lpj Ooi
London Lpj Ooi
LLLinda A Lee
Linda A Lee

8 February 2016 in Leukemia
Verified
Journal Article
Open access
MNM-L Nairismägi
M-L Nairismägi
JTJ Tan
J Tan
JLJing Quan Lim
Jing Quan Lim
SNS Nagarajan
S Nagarajan
CNC C Y Ng
C C Y Ng
CKChoon Kiat Kiat
Choon Kiat Kiat
Epitheliotropic intestinal T-cell lymphoma (EITL, also known as type II enteropathy-associated T-cell lymphoma) is an aggressive intestinal disease with poor prognosis and its molecular alterations have not been comprehensively characterized. We aimed to identify actionable easy-to-screen alterations that would allow better diagnostics and/or treatment of this deadly disease. By performing whole-exome sequencing of four EITL tumor-normal pairs, followed by amplicon deep sequencing of 42 tumor samples, frequent alterations of the JAK-STAT and G protein-coupled receptor (GPCR) signaling pathways were discovered in a large portion of samples. Specifically, STAT5B was mutated in a remarkable 63% of cases, JAK3 in 35% and GNAI2 in 24%, with the majority occurring at known activating hotspots in key functional domains. Moreover, STAT5B locus carried copy-neutral loss of heterozygosity resulting in the duplication of the mutant copy, suggesting the importance of mutant STAT5B dosage for the development of EITL. Dysregulation of the JAK-STAT and GPCR pathways was also supported by gene expression profiling and further verified in patient tumor samples. In vitro overexpression of GNAI2 mutants led to upregulation of pERK1/2, a member of MEK-ERK pathway. Notably, inhibitors of both JAK-STAT and MEK-ERK pathways effectively reduced viability of patient-derived primary EITL cells, indicating potential therapeutic strategies for this neoplasm with no effective treatment currently available.